A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
Latest Information Update: 19 Mar 2024
At a glance
- Drugs AT 193 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors Azora Therapeutics
- 12 Mar 2024 Status changed from active, no longer recruiting to completed.
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2022 Planned End Date changed from 15 Jun 2022 to 1 Feb 2023.